Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?
Open Access
- 22 October 2026
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
Abstract
Pregnant and breastfeeding individuals are routinely excluded from clinical drug development, creating persistent evidence gaps in pharmacology, safety, and dosing. Despite mandatory contraception and pregnancy testing, unintended pregnancies occur, particularly during the development of central nervous system (CNS) medicines used by women of reproductive age. Once exposure to an investigational medicinal product (IMP) has occurred, these pregnancies may provide valuable prospective human data; however, treatment or trial participation is often discontinued and follow‐up may be incomplete. This study assessed how unintended pregnancies and breastfeeding data were reported, managed, and evaluated in clinical trials supporting marketing authorization applications (MAAs) for CNS products. We reviewed 35 MAAs for centrally authorized CNS products submitted to the European Medicines Agency between 2012 and 2022. Pregnancy frequency, IMP exposure, pregnancy outcomes, breastfeeding data and regulatory comments were extracted from MAA dossiers, Day 120 Lists of Questions and Summaries of Product Characteristics. Overall, 451 pregnancies were identified, including 343 with IMP exposure. Of these, 108 occurred in pivotal phase 3 trials, resulting in 39 live births, 23 elective terminations, 17 spontaneous pregnancy losses, and 29 unknown or ongoing outcomes. Regulators raised 19 pregnancy‐related and six breastfeeding‐related concerns. Only one dossier included a dedicated human lactation study. Pregnancy reporting varied substantially in location, format and case‐level detail, while 27% of pivotal IMP‐exposed pregnancies had unknown or ongoing outcomes at assessment. More structured reporting and follow‐up, including relevant exposure and pharmacokinetic data where feasible, could strengthen clinical pharmacology and regulatory evidence and support more informative product information.Keywords
This publication has 32 references indexed in Scilit:
- Off‐label use of drugs in pregnancy: A critical review of guidelines, current practices, and a clinical perspectiveInternational Journal of Gynecology & Obstetrics, 2025
- EMA perspective on the value of model‐informed drug development for labeling recommendations regarding medicine use during pregnancy and breastfeedingCPT: Pharmacometrics & Systems Pharmacology, 2024
- National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysisThe Lancet, 2023
- Core Data Elements for Pregnancy Pharmacovigilance Studies Using Primary Source Data Collection Methods: Recommendations from the IMI ConcePTION ProjectDrug Safety, 2023
- Science‐Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical LabelsClinical Pharmacology & Therapeutics, 2022
- Contraception Selection, Effectiveness, and Adverse EffectsJAMA, 2021
- Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy lossThe Lancet, 2021
- Measurement and meaning: reporting sex in health researchThe Lancet, 2019
- Contraceptive failure in the United StatesContraception, 2011
- Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimesterAmerican Journal of Obstetrics and Gynecology, 1989